RBC: 'We have just confirmed that a recent clinicaltrials.gov listing for a new drug called BIIB145'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $210.00 price target on Biogen (NASDAQ: BIIB).The analyst comments "We ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
